Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Rhea-AI Summary
Akari Therapeutics (Nasdaq: AKTX) announced its participation in the Virtual Investor “Why Now” on-demand conference held on August 27, 2026. President and CEO Abizer Gaslightwala presented the company’s investment thesis, focusing on the evolving antibody drug conjugate (ADC) market, demand for differentiated payload technologies, and Akari’s proprietary PH1 RNA splicing payload platform, which is designed to address limitations of conventional ADC payloads. The video webcast is available for on-demand viewing, and Akari notes that JTC Team and Virtual Investor Co. are paid investor relations and communications consultants. The company emphasizes the webcast does not constitute an offer to purchase securities and encourages investors to conduct their own due diligence via its website and SEC filings.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 18 | Preclinical data | Positive | +5.0% | Urothelial cancer data supported differentiated ADC activity in resistant tumor models. |
| Aug 13 | Quarterly results | Positive | +7.7% | Financing, pipeline progress, collaboration, and preclinical data accompanied quarterly results. |
| Aug 04 | CEO update | Positive | +5.8% | CEO discussed Whitehawk collaboration and the PH1 payload platform strategy. |
| Jul 21 | Research collaboration | Positive | -12.8% | Whitehawk collaboration launched preclinical dual-payload ADC research workstreams. |
| Jul 07 | Advisory appointment | Positive | +42.0% | Patricia LoRusso joined the scientific advisory board to support AKTX-101 development. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Four of five recent positive-news events aligned with positive 24-hour reactions, while the July 21 partnership announcement diverged with a -12.8% reaction.
Key Terms
antibody drug conjugates medical
rna splicing medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Video webcast now available here
TAMPA, Fla. and LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that it participated in the Virtual Investor "Why Now" on-demand conference.
During the webcast, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, presented the Company's investment thesis, highlighting why he believes now is a pivotal time for Akari. The discussion highlights the rapidly evolving ADC landscape, increasing industry demand for differentiated payload technologies, and Akari's proprietary PH1 RNA splicing payload platform, which is designed to address limitations associated with conventional ADC payloads.
The video webcast is now accessible for on-demand viewing here.
JTC Team and Virtual Investor Co. are paid consultants to Akari Therapeutics, Plc. JTC Team and Virtual Investor Co. are investor relations and corporate communications firms. Any content included in this release shall not be construed as an offer to purchase securities of Akari Therapeutics, Plc. Interested parties are responsible for conducting their own due diligence and are encouraged to review the Company's website and the SEC website for the latest information and filings on the Company.
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing. Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any antigen target of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a proprietary linker, enabling it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. Unlike current ADCs that use microtubule inhibitors and DNA-damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating both the innate and adaptive immune systems to drive robust and durable activity. In preclinical studies, AKTX-101 has been shown to have significant activity and prolonged survival relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors. The PH1 payload has also been demonstrated to be very active against cancer cells with key oncogenic drivers such as KRAS, BRAF, ARV7, FGFR3 fusions, and others. The Company has initiated IND enabling studies for AKTX-101 with a goal of starting its First-In-Human trial by mid-2027. Akari is also developing AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen broadly expressed across multiple solid tumors. AKTX-102 is designed to leverage Akari’s proprietary PH1 spliceosome-modulating payload and a novel antibody construct to enable differentiated tumor cell killing and immune activation.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and the timing of commencement of a Phase I clinical trial. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company’s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
